ESC 365 - Pathogenic variants in titin predispose to anthracycline cardiotoxicity: insights from an hiPSC-CM model

ESC2025 Premium Access

Pathogenic variants in titin predispose to anthracycline cardiotoxicity: insights from an hiPSC-CM model

Session: Anticipating risk to protect the heart during cancer treatment

Topic: Stratification, Prevention and Monitoring

Speaker: Doctor H. Boen (Wilrijk, BE)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Hanne Boen

Wilrijk (Belgium)

1 presentation

0 follower

5 more presentations in this session

Use of direct oral anticoagulants in patients with atrial fibrillation and cancer: a subanalysis of the nationwide Italian START registry

Speaker: Doctor V. Cormaci (Rome, IT)

Atorvastatin and left ventricular global longitudinal strain during anthracycline-based chemotherapy

Speaker: Doctor V. Juhasz (Boston, US)

Impact of anemia on clinical outcomes of active cancer patients with low-risk pulmonary embolism receiving rivaroxaban: insight from the ONCO PE trial

Speaker: Doctor R. Chatani (Kurashiki, JP)

Cardiovascular adverse events in primary lung cancer patients treated with immune checkpoint inhibitors: a nationwide database study

Speaker: Doctor T. Isawa (Sendai, JP)

Improved risk stratification with SCORE2 on top of HFA-ICOS in cancer patients without previous cardiovascular disease

Speaker: Mrs M. Gynnild (Trondheim, NO)

Access the full session

Anticipating risk to protect the heart during cancer treatment

Speakers: Doctor H. Boen, Doctor V. Cormaci, Doctor V. Juhasz, Doctor R. Chatani, Doctor T. Isawa...

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources